Promoter Hypermethylation of the MEG3 (DLK1/MEG3) Imprinted Gene in Multiple Myeloma

Clin Lymphoma Myeloma. 2008 Jun;8(3):171-5. doi: 10.3816/CLM.2008.n.021.

Abstract

Background: Methylation represents the most studied epigenetic modification and results in the silencing of genes involved in various processes such as differentiation and cell-cycle regulation. MEG3 represents an imprinted gene maternally expressed in humans that encodes a nontranslated product. In this survey, we studied the methylation status of the specific gene in multiple myeloma (MM).

Patients and methods: Twenty-one patients with MM (17 with immunoglobulin [Ig] G, 3 with IgA, and 1 with IgM) were evaluated using methylation-specific polymerase chain reaction (after DNA bisulphite modification).

Results: Promoter hypermethylation was observed in 12 (57.14%) bone marrow samples and in 9 of 14 (64.28%) available peripheral blood samples. A correlation with disease stage was also observed and also with the disease subtype (IgG, 64.7%; IgA, 0; IgM, 100%).

Conclusion: We conclude that promoter hypermethylation of the differentially methylated region of the MEG3 imprinted gene is observed in patients with MM.

MeSH terms

  • Aged
  • Aged, 80 and over
  • DNA Methylation*
  • Female
  • Genomic Imprinting*
  • Humans
  • Immunoglobulins / blood
  • Immunoglobulins / genetics
  • Male
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / genetics*
  • Promoter Regions, Genetic*
  • Prospective Studies
  • Proteins / genetics*
  • Proteins / metabolism
  • RNA, Long Noncoding

Substances

  • Immunoglobulins
  • M-proteins (Myeloma)
  • MEG3 non-coding RNA, human
  • Proteins
  • RNA, Long Noncoding